NCT06501625
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06501625 |
| Title | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Institut de Recherches Internationales Servier |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | FRA | ESP | DEU | CAN | BRA | AUS |
CKB BOOST